NPHLA Daily
NPHLA Daily
Tuesday, October 27, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 3 trial updates, 2 new studies
NPHLA tracked 5 new official records on this desk today: 3 trial updates, 2 new studies. First: New trial registered: Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Metabolic signal
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie: “Mesenchymal stromal cell-based therapies for obesity-associated metabolic complications: Mechanistic insights,…
Regulatory signal
What changed today in Regulatory: 1 recall record
NPHLA tracked 1 new official record on this desk today: 1 recall record. First: Class II: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX… — reason given: Lack of assurance of sterility.…
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 1 trial update
NPHLA tracked 1 new official record on this desk today: 1 trial update. First: New trial registered: EMG-Guided Versus Endoscopic-Catheter Botulinum Toxin Injection for Spasmodic Dysphonia
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 3 trial updates, 2 new studies
- What changed today in Metabolic: 1 new study
- What changed today in Regulatory: 1 recall record
- What changed today in Aesthetics & Longevity: 1 trial update
- Class II recall: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage… (U.S. Food and Drug Administration (Enforcement Report))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.